No problem. This is pretty big news in my book. I am surprised more aren't interested. By being able to compare the Cohort 2 and Cohort 2a data essentially we will be getting a sneak peak into what we can except from Phase II.
This study is a Phase I/II, open-label, non randomized, sequential, multi-center clinical trial. There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better vision cohort will contain 4 patients.
Both SMD and AMD trials now have an extra cohort, Cohort 2a. This cohort will be made up of patients with "better vision" than the previous protocol allowed, and will be treated with 100K cells. It seems as though Cohort 2a can be treated independent of the other cohorts, but I need to verify that.
I think this is a very good move by ACT. By treating Cohort 2a with 100K cells, they will be able to compare data with the previously treated Cohort 2 (100K dose group) and see if there are any changes in results by treating earlier stage patients.